Tags

Type your tag names separated by a space and hit enter

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.

Abstract

BACKGROUND

A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory cells involved in triggering exacerbations of COPD. The objective of the current study was to evaluate roflumilast for its contribution to phagocytic activity in COPD patients.

METHODS

Twenty-one patients diagnosed with COPD received roflumilast once daily for 6 months in combination with fluticasone (an inhaled corticosteroid), salmeterol (a long-acting β2-agonist), and tiotropium (a long-acting muscarinic antagonist) or combinations of these agents. The main inclusion criterion was stable disease for at least the previous 30 days. Neutrophils and spirometric changes, ie, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), were measured in the COPD patients at indicated time points. The first sample was taken before receiving roflumilast, the second 3 months later, and the third after 6 months. Examination of defective phagocytosis was done by flow cytometry using a FagoFlowEx(®) kit. The statistical analysis was performed using Statistica software.

RESULTS

Our results indicate that phagocytic activity was increased after 3 and 6 months of treatment when compared with baseline (P<0.001). Similarly, FVC and FEV1 were also increased during the 6-month period, but only FVC differed significantly from baseline (P<0.001).

CONCLUSION

Although the number of patients in this study was limited, our results indicate that roflumilast induces phagocytic activity, which improves lung function.

Authors+Show Affiliations

Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department, Immunology and Histocompatibility Laboratory, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department, Immunology and Histocompatibility Laboratory, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department, Immunology and Histocompatibility Laboratory, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.Pulmonary Department-Oncology Unit, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Pub Type(s)

Clinical Study
Journal Article

Language

eng

PubMed ID

26109853

Citation

Porpodis, Konstantinos, et al. "Roflumilast, a Phosphodiesterase-4 Inhibitor, Induces Phagocytic Activity in Greek COPD Patients." International Journal of Chronic Obstructive Pulmonary Disease, vol. 10, 2015, pp. 1123-8.
Porpodis K, Domvri K, Zarogoulidis P, et al. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1123-8.
Porpodis, K., Domvri, K., Zarogoulidis, P., Petridis, D., Tsirgogianni, K., Papaioannou, A., Hatzizisi, O., Kioumis, I., Liaka, A., Kikidaki, V., Lampaki, S., Organtzis, J., & Zarogoulidis, K. (2015). Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients. International Journal of Chronic Obstructive Pulmonary Disease, 10, 1123-8. https://doi.org/10.2147/COPD.S83205
Porpodis K, et al. Roflumilast, a Phosphodiesterase-4 Inhibitor, Induces Phagocytic Activity in Greek COPD Patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1123-8. PubMed PMID: 26109853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients. AU - Porpodis,Konstantinos, AU - Domvri,Kalliopi, AU - Zarogoulidis,Paul, AU - Petridis,Dimitrios, AU - Tsirgogianni,Katerina, AU - Papaioannou,Antonis, AU - Hatzizisi,Olga, AU - Kioumis,Ioannis, AU - Liaka,Alexandra, AU - Kikidaki,Violeta, AU - Lampaki,Sofia, AU - Organtzis,John, AU - Zarogoulidis,Konstantinos, Y1 - 2015/06/15/ PY - 2015/6/26/entrez PY - 2015/6/26/pubmed PY - 2016/3/22/medline KW - COPD KW - phosphodiesterase-4 inhibitors KW - roflumilast SP - 1123 EP - 8 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 10 N2 - BACKGROUND: A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory cells involved in triggering exacerbations of COPD. The objective of the current study was to evaluate roflumilast for its contribution to phagocytic activity in COPD patients. METHODS: Twenty-one patients diagnosed with COPD received roflumilast once daily for 6 months in combination with fluticasone (an inhaled corticosteroid), salmeterol (a long-acting β2-agonist), and tiotropium (a long-acting muscarinic antagonist) or combinations of these agents. The main inclusion criterion was stable disease for at least the previous 30 days. Neutrophils and spirometric changes, ie, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), were measured in the COPD patients at indicated time points. The first sample was taken before receiving roflumilast, the second 3 months later, and the third after 6 months. Examination of defective phagocytosis was done by flow cytometry using a FagoFlowEx(®) kit. The statistical analysis was performed using Statistica software. RESULTS: Our results indicate that phagocytic activity was increased after 3 and 6 months of treatment when compared with baseline (P<0.001). Similarly, FVC and FEV1 were also increased during the 6-month period, but only FVC differed significantly from baseline (P<0.001). CONCLUSION: Although the number of patients in this study was limited, our results indicate that roflumilast induces phagocytic activity, which improves lung function. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/26109853/Roflumilast_a_phosphodiesterase_4_inhibitor_induces_phagocytic_activity_in_Greek_COPD_patients_ L2 - https://dx.doi.org/10.2147/COPD.S83205 DB - PRIME DP - Unbound Medicine ER -